Oric Pharmaceuticals
ORIC
54 hedge funds and large institutions have $552M invested in Oric Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 17 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
1.98% more ownership
Funds ownership: 71.95% → 73.94% (+2%)
18% less funds holding
Funds holding: 66 → 54 (-12)
23% less capital invested
Capital invested by funds: $722M → $552M (-$169M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
71% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 17
Top Buyers
Top Sellers
ORIC Hedge Fund Activity: Q3 2020 in Review
54 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q3 2020, worth a combined $552M — down 23% from $722M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ORIC and 5 opened new positions — a net loss of 12 holders — while 15 trimmed existing stakes and 20 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $17.5M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $16.8M sold.
- 54 institutional investors held Oric Pharmaceuticals (ORIC) as of Q3 2020, down from 66 in Q2 2020.
- Funds reported $552M of Oric Pharmaceuticals stock for Q3 2020, down 23% quarter-over-quarter.
- 5 funds opened new Oric Pharmaceuticals positions in Q3 2020 and 17 closed out, a net change of -12 holders.
- The largest Oric Pharmaceuticals buyer in Q3 2020 was ArrowMark Colorado Holdings, an estimated $17.5M added.
- The largest Oric Pharmaceuticals seller in Q3 2020 was Foresite Capital Management III, an estimated $16.8M sold.
Based on aggregated 13F filings for Q3 2020.